Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Rhea-AI Summary

Nektar Therapeutics (NKTR) has scheduled its Q3 2024 financial results announcement for Thursday, November 7, 2024, after U.S. market close. CEO Howard Robin will host a conference call at 5:00 p.m. ET/2:00 p.m. PT to discuss the results. The press release and audio webcast will be accessible through the company's website, with the webcast replay available until December 7, 2024. Pre-registration is required for conference call access.

News Market Reaction – NKTR

+3.36%

1 alert

+3.36% News Effect

On the day this news was published, NKTR gained 3.36%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through December 7, 2024.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts:

For Investors:                                                                                             
Vivian Wu of Nektar Therapeutics
(628) 895-0661

For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-2024-on-thursday-november-7-2024-after-close-of-us-based-financial-markets-302293320.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar (NKTR) release Q3 2024 earnings?

Nektar Therapeutics will release its Q3 2024 earnings on Thursday, November 7, 2024, after the U.S. financial markets close.

What time is Nektar's (NKTR) Q3 2024 earnings call?

Nektar's Q3 2024 earnings conference call is scheduled for 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time on November 7, 2024.

How long will Nektar's (NKTR) Q3 2024 earnings call replay be available?

The webcast replay of Nektar's Q3 2024 earnings call will be available through December 7, 2024.

How can I access Nektar's (NKTR) Q3 2024 earnings call?

Participants must pre-register through the Nektar Earnings Call Registration link. Registrants will receive dial-in information and a PIN for call access.